GLP-1 Agonists and Orthostatic Hypotension/Hyponatremia
GLP-1 receptor agonists do not typically cause orthostatic hypotension; in fact, they may actually protect against postprandial hypotension, though they can cause modest tachycardia. Regarding hyponatremia, this is not a recognized common adverse effect, though one recent case report suggests a potential association when combined with thiazide diuretics.
Orthostatic Hypotension
The evidence regarding blood pressure effects is reassuring:
GLP-1 agonists actually attenuate hypotensive responses rather than cause them. In a study of older individuals and patients with type 2 diabetes, intravenous GLP-1 attenuated the fall in both systolic and diastolic blood pressure after oral glucose administration 1. This protective effect appears mediated through slowing gastric emptying and decreasing mesenteric blood flow.
The most recent comprehensive guideline (2024) lists cardiac arrhythmia/tachycardia as a potential adverse effect requiring monitoring, but notably does not list orthostatic hypotension 2.
Heart rate typically increases by approximately 5 beats per minute with GLP-1 receptor agonists, but this has not been associated with higher blood pressure or other adverse cardiovascular events 3.
Important Caveat for Volume Depletion
While GLP-1 agonists themselves don't cause orthostatic hypotension, there is one clinical scenario requiring vigilance:
- Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 15-20% of patients and could theoretically lead to volume depletion 3.
- When combined with SGLT2 inhibitors (which have diuretic effects), patients should be monitored for signs of volume depletion such as orthostatic lightheadedness 4.
- The elderly or those on concurrent diuretic therapy warrant closer monitoring for volume status.
Hyponatremia
Hyponatremia is not listed as a common or recognized adverse effect in any major guidelines 2, 3, 4, 5, 2, 6, 7.
However, one very recent case report (2026) describes a temporal association:
- A 73-year-old woman on chronic chlorthalidone developed recurrent symptomatic hyponatremia with tirzepatide escalation (from 7.5 mg to 10 mg weekly) 8.
- Sodium normalized after discontinuing tirzepatide, suggesting a possible drug interaction with thiazide-like diuretics.
- This represents a single case report and does not establish causation, but suggests monitoring sodium may be prudent when GLP-1 agonists are combined with medications affecting sodium balance.
Clinical Recommendations
For routine practice:
- Do not avoid GLP-1 agonists due to concerns about orthostatic hypotension—they may actually be protective
- Monitor for tachycardia (expected ~5 bpm increase), which is generally benign
- Ensure adequate hydration, especially during dose titration when GI side effects are most common
- Consider baseline and periodic sodium monitoring if combining with thiazide or thiazide-like diuretics, particularly in elderly patients
Red flags requiring closer monitoring:
- Elderly patients
- Concurrent diuretic use (especially thiazides)
- Severe or persistent nausea/vomiting/diarrhea leading to poor oral intake
- Combination therapy with SGLT2 inhibitors (additive diuretic effects)
The cardiovascular benefits of GLP-1 agonists—including reduced major adverse cardiovascular events, heart failure hospitalizations, and cardiovascular death—far outweigh these minimal concerns 2.